MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.
|Address:||Milstein Building, Granta Park , Cambridge|
|Membership type:||Founder Member|
MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline. It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.
MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden
MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented. With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.
1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline
MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.
AstraZeneca has announced the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm.
31 October 2013Read in full
MedImmune Cambridge was pleased to support the Society of Biology’s ‘Big Biology Day’ at Hills Road Sixth Form College on Saturday 12 October 2013, held in partnership with the University of Cambridge Science Festival.
16 October 2013Read in full
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
27 August 2013Read in full
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.
18 June 2013Read in full
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme
8 April 2013Read in full
A leading scientist based at Medimmune’s Granta Park headquarters has been named as one of the 100 most inspiring people in the life sciences industry by a US magazine.
30 August 2011Read in full
MedImmune opens a new biologics research and development facility in Cambridge called the Aaron Klug Building. The building is named after the 1982 Nobel prize winner for chemistry, Sir Aaron Klug.
17 October 2008Read in full